- Home
- ADIL vs QLGN Comparison
ADIL vs QLGN Comparison
Compare ADIL & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- QLGN
- Stock Information
- Founded
- ADIL 2010
- QLGN 1996
- Country
- ADIL United States
- QLGN United States
- Employees
- ADIL N/A
- QLGN N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- QLGN Health Care
- Exchange
- ADIL Nasdaq
- QLGN Nasdaq
- Market Cap
- ADIL 7.7M
- QLGN 7.4M
- IPO Year
- ADIL 2018
- QLGN N/A
- Fundamental
- Price
- ADIL $0.36
- QLGN $2.97
- Analyst Decision
- ADIL Strong Buy
- QLGN
- Analyst Count
- ADIL 2
- QLGN 0
- Target Price
- ADIL $4.75
- QLGN N/A
- AVG Volume (30 Days)
- ADIL 745.1K
- QLGN 3.7M
- Earning Date
- ADIL 11-12-2025
- QLGN 11-13-2025
- Dividend Yield
- ADIL N/A
- QLGN N/A
- EPS Growth
- ADIL N/A
- QLGN N/A
- EPS
- ADIL N/A
- QLGN N/A
- Revenue
- ADIL N/A
- QLGN N/A
- Revenue This Year
- ADIL N/A
- QLGN N/A
- Revenue Next Year
- ADIL N/A
- QLGN N/A
- P/E Ratio
- ADIL N/A
- QLGN N/A
- Revenue Growth
- ADIL N/A
- QLGN N/A
- 52 Week Low
- ADIL $0.22
- QLGN $1.61
- 52 Week High
- ADIL $1.30
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- ADIL 47.93
- QLGN 39.28
- Support Level
- ADIL $0.35
- QLGN $3.28
- Resistance Level
- ADIL $0.39
- QLGN $5.97
- Average True Range (ATR)
- ADIL 0.03
- QLGN 0.57
- MACD
- ADIL -0.00
- QLGN -0.21
- Stochastic Oscillator
- ADIL 27.67
- QLGN 2.28
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.